Psma-targeted radiopharmaceuticals for treatment of cancer

CR20260079APending Publication Date: 2026-05-20FUSION PHARMA INC

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: CR202600079
Authority / Receiving Office: CR · CR
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-07-26
Filing Date: 2024-07-26
Publication Date: 2026-05-20

Application Information

Patent Timeline

26 Jul 2024

Priority

26 Jul 2024

Application

CR202600079

20 May 2026

Publication

CR20260079A

IPC: C07K5/037; A61K47/12; A61K47/18; A61K47/22; A61K51/08; A61P35/00

CPC: A61K47/12; A61K47/22; A61P35/00; C07K5/0215; A61K47/183; A61K47/186; A61K9/0019; A61K51/0497

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

Pharmaceutical compositions comprising radioconjugate 225 This document discloses the formulation I and methods of its use for the treatment of PSMA-expressing cancer. Methods for preparing these pharmaceutical compositions are also disclosed herein.

Need to check novelty before this filing date? Find Prior Art